Abstract 4111
Background
Molecular heterogeneity drives tumour evolution and resistance to therapies. Because of biopsy challenges in non-small cell lung cancer (NSCLC), few studies compared the molecular profile between primary tumour (PT) and metastasis (Met). Here, we compare somatic single-nucleotide variants (SNVs), tumour mutational burden (TMB) and expression profiles between PT and matched metachronous Met in NSCLC patients (pts).
Methods
DNA and RNA were extracted from 14 matched fresh-frozen samples and PBMCs from 7 pts treated at the Institut d’Oncologie Thoracique (Gustave Roussy, GR) between 2011 and 2015. GATK4 Mutect2 were used for SNV calling and TMB on whole exome sequencing. Salmon was used for expression counts from RNAseq; Z-scores were computed by comparing data to 158 other NSCLC RNAseq from GR molecular profiling trials; GSVA R package was use to assess single sample gene set enrichment score (ssGSEA).
Results
Median age was 67 yo (62-78); 4/7 metastases were biopsied after chemotherapy; histology was adenocarcinoma (6) or large cell carcinoma (1). The median number of SNVs unique to PT or Met was 50 (10-143) or 79 (36-324), respectively; it was 65 (0-110) for shared SNVs; 6/7 pts had known driver alterations (TP53, KRAS, PIK3CA) in both lesions; one Met acquired a pathogenic KRAS G35C mutation. Median TMB was 3.9 (0.3-4.3) in PT and 4.1 (2.2-8.4) in Met. Genes with top negative Z-scores (MRFAP1, EP400, RIOX1, DDX27) were shared between PT and Met in 6/7 pts; genes with top positive Z-score were unique. ssGSEA-enriched genesets were shared between PT and Met; top enriched hallmarks included Myc targets, Mitotic Spindle, DNA repair, oxidative phosphorylation and TGFb signaling.
Conclusions
Matched comparison of molecular profiles between PT and Met evidence shared and unique alterations; this informs on tumor evolution and may help guiding treatment choice.
Clinical trial identification
Editorial acknowledgement
AK: AK was funded by the DUERTECC Gustave Roussy program
LCD: LCD was funded by the INSERM ATIP-Avenir grant from SPV
Legal entity responsible for the study
Sophie Postel-Vinay.
Funding
Cancéropole d’Ile de France.
Disclosure
A Kawachi: Funded by the DUERTECC Gustave Roussy program. L. Colmet-Daage: Funded by the INSERM ATIP-Avenir grant from SPV. L. Verlingue: Honoraria (self): Adaptherapy; Research grant / Funding (self): Bristol-Myers Squibb. D. Planchard: Honoraria (self): AstraZeneca; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Celgene; Honoraria (self): Eli Lilly; Honoraria (self): Merck; Honoraria (self): Novartis; Honoraria (self): Pfizer; Honoraria (self): prIME Oncology; Honoraria (self): Peer CME; Honoraria (self): Roche; Travel / Accommodation / Expenses: AstraZeneca; Travel / Accommodation / Expenses: Bristol-Myers Squibb; Travel / Accommodation / Expenses: Boehringer Ingelheim ; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Merck; Travel / Accommodation / Expenses: Novartis; Travel / Accommodation / Expenses: prIME Oncology; Travel / Accommodation / Expenses: Pfizer. A. Hollebecque: Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Janssen Cilag; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Sanofi. C. Massard: Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): BMS; Research grant / Funding (self): Boehringer Ingelheim; Research grant / Funding (self): Janssen Cilag; Research grant / Funding (self): Merck, Novartis; Research grant / Funding (self): Pfizer; Research grant / Funding (self): Roche; Research grant / Funding (self): Sanofi; Advisory / Consultancy: Amgen; Advisory / Consultancy: Astellas; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Bayer; Advisory / Consultancy: BeiGene; Advisory / Consultancy: BMS; Advisory / Consultancy: Celgene; Advisory / Consultancy: Debiopharm; Advisory / Consultancy: Genentech; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Janssen; Advisory / Consultancy: Lilly. B. Besse: Research grant / Funding (self): Abbvie; Research grant / Funding (self): Amgen; Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): Biogen; Research grant / Funding (self): Blueprint Medicines; Research grant / Funding (self): BMS; Research grant / Funding (self): Celgene; Research grant / Funding (self): Eli Lilly; Research grant / Funding (self): GSK; Research grant / Funding (self): Ignyta; Research grant / Funding (self): IPSEN; Research grant / Funding (self): Merck KGaA; Research grant / Funding (self): MSD; Research grant / Funding (self): Nektar; Research grant / Funding (self): Onxeo; Research grant / Funding (self): Pfizer; Research grant / Funding (self): Pharma Mar; Research grant / Funding (self): Sanofi; Research grant / Funding (self): Spectrum Pharmaceuticals; Research grant / Funding (self): Takeda. J. Soria: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Astex; Advisory / Consultancy: Clovis; Advisory / Consultancy: GSK; Advisory / Consultancy: GamaMabs; Advisory / Consultancy: Lilly; Advisory / Consultancy: MSD; Advisory / Consultancy: Mission Therapeutics; Advisory / Consultancy: Merus; Advisory / Consultancy: Pfizer; Advisory / Consultancy: PharmaMar; Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: Roche/Genentech; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Servier; Advisory / Consultancy: Symphogen; Advisory / Consultancy: Takeda; Full / Part-time employment: AstraZeneca. S. Postel Vinay: Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): BMS; Research grant / Funding (self): Boehringer Ingelheim; Research grant / Funding (self): Janssen Cilag; Research grant / Funding (self): Merck; Research grant / Funding (self): Novartis; Research grant / Funding (self): Pfizer; Research grant / Funding (self): Roche; Research grant / Funding (self): Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
1945 - Randomized Phase II Study of Trabectedin/Olaparib Compared to Physician’s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies.
Presenter: Christoph Heilig
Session: Poster Display session 3
Resources:
Abstract
3021 - Homogenisation of Leftover Surgical Tissue across multiple cancer types: a Feasibility Study (HoLST-F)
Presenter: Lavinia Spain
Session: Poster Display session 3
Resources:
Abstract
2882 - Safety, efficacy, and immune effects of intratumoral tilsotolimod in patients with refractory solid tumors: updated results from ILLUMINATE-101
Presenter: Hani Babiker
Session: Poster Display session 3
Resources:
Abstract
1950 - Phase 1 Dose Escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumors: Updated results
Presenter: Erkut Borazanci
Session: Poster Display session 3
Resources:
Abstract
2391 - A phase 1 study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
Presenter: Anna Spreafico
Session: Poster Display session 3
Resources:
Abstract
5692 - FPA150 (B7-H4 antibody) Phase 1 Update in Advanced Solid Tumors: Monotherapy and in Combination with Pembrolizumab
Presenter: Zev Wainberg
Session: Poster Display session 3
Resources:
Abstract
2416 - MG1124, a novel CEACAM1-targeted monoclonal antibody, has therapeutic potential as a combination partner of PD-1 inhibitors in NSCLC patients
Presenter: Eun Hee Lee
Session: Poster Display session 3
Resources:
Abstract
2661 - Tumor stroma targeting and modulation by OMTX705 ADC, a novel and potent immunotherapeutic treatment of solid tumors.
Presenter: Myriam Fabre
Session: Poster Display session 3
Resources:
Abstract
3681 - Durvalumab + monalizumab, mFOLFOX6, and bevacizumab in patients (pts) with metastatic microsatellite-stable colorectal cancer (MSS-CRC)
Presenter: May Cho
Session: Poster Display session 3
Resources:
Abstract
2664 - Phase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy
Presenter: Nicholas Mach
Session: Poster Display session 3
Resources:
Abstract